Related Experiment Videos

[Basic studies of cefmenoxime]

Insights

Cefmenoxime (CMX) is rapidly excreted in children aged 8-13 after a 50 mg/kg dose, with both intravenous injection and drip infusion showing quick elimination and short biological half-lives for this antibiotic.

Area of Science:

  • Pharmacology
  • Pediatric Medicine
  • Antibiotic Research

Context:

  • Cefmenoxime (CMX) is a third-generation cephalosporin antibiotic.
  • Pediatric dosing and pharmacokinetic data are crucial for effective and safe antibiotic use.
  • Understanding drug elimination is vital for optimizing treatment regimens.

Purpose:

  • To evaluate the blood levels and urinary excretion of cefmenoxime (CMX) in pediatric patients.
  • To compare the pharmacokinetics of CMX following intravenous injection versus 1-hour drip infusion.
  • To determine the biological half-life and excretion rates of CMX in children aged 8 to 13 years.

Summary:

  • Children (8-13 years) received a 50 mg/kg dose of cefmenoxime (CMX) via intravenous injection or 1-hour drip infusion.
  • Intravenous injection resulted in mean blood levels of 125.0 µg/ml at 0.5 hours, with a half-life of ~0.7 hours and 64.1% urinary excretion by 6 hours.
  • Drip infusion showed mean levels of 115.5 µg/ml post-infusion, a half-life of ~0.8 hours, and 56.5% urinary excretion by 6 hours.

Impact:

  • Cefmenoxime (CMX) demonstrates rapid excretion in pediatric patients at a high dosage.
  • The findings suggest that CMX is eliminated quickly, influencing potential redosing strategies.
  • This pharmacokinetic data aids in understanding CMX behavior in children, informing clinical practice.

Related Concept Videos